Our focus is on research, acquisition, development, licensing, and marketing of
pharmaceutical products but we benefit from being part of a global family of specialists.
Each division can utilise the experience of the Kowa Company, Ltd. network to ensure
that processes are streamlined and constantly evolving to meet the needs of all
Kowa Pharmaceutical Europe Co. Ltd. is a specialty pharmaceutical company located in the UK focused primarily on cardiometabolic therapeutics.
It was established in 2000 after the clinical research focused Kowa Research Europe Ltd. had been founded in 1999. These European pharmaceutical divisions of Kowa Company, Ltd. are committed to ground-breaking drug research, development and marketing. Together they seek to ensure quality products are made available to people within Europe and beyond, looking to contribute to a better standard of health and a more comfortable life for all. Find out more.
12 Jun 2012
Two papers published in the European Journal of Preventive Cardiology
27 Jun 2011
Pitavastatin consistently demonstrates sustained increases in HDL-C
27 Jun 2011
New European Atherosclerosis Society’s guidance highlights need to target triglycerides
“Kowa is committed to the healthcare global community.”
Our entrepreneurial initiative means we’re determined to meet future needs.
Since 2003, pitavastatin has accumulated over 4 million patient-years of exposure.